by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Bio Technology : October 2009
Volume 19 • Number 3 • October 2009 Australasian BioTechnology 15 MASTER YOUR SCIENCE SMARTS Postgraduate opportunities in Biotechnology Be at the forefront of cutting-edge science and provide practical solutions to everyday problems. Commonwealth supported places (CSP) are available for 2010 in the Master of Biotechnology program, with opportunities to specialise in: Food Science & Technology ■ Clinical Microbiology ■ Environmental & Agricultural Biotechnology ■ Food Microbiology ■ CSP also available for the Master of Biotechnology and Business. This means the government will contribute towards the cost, so you’ll pay less for your postgraduate qualifcation. Postgraduate Information Session > Thursday 22 October 2009 Anytime 4.30 - 6.30 pm State Library of Victoria. Access via Entry 3 on La Trobe Street (between Russell and Swanston streets) For more information email firstname.lastname@example.org or phone 9925 2533. www.rmit.edu.au/seh/sciences S1358 Partnerships are CSL’s Future CSL Limited is a fully integrated global biopharmaceutical company that researches, develops, manufactures and markets products worldwide to treat and prevent serious medical conditions. CSL continues to expand its R&D portfolio by supporting early stage research, ensuring access to a pipeline of poten- tial product candidates for future development. Core capa- bilities are in three main areas of new product development; Protein Replacement Therapies (building on CSL's existing plasma medicine business), Therapeutic Proteins (focusing on recombinant proteins and antibodies) and Immunomodu- lators (based on CSL's proprietary ISCOMATRIX® adjuvant). Prime areas of clinical interest are oncology, inflammation and infectious diseases. Research Activities CSL's research group in Melbourne focuses on the creation and evaluation of novel recombinant protein-based thera- peutics. The activities of this group are world class in the following areas: Analytical protein chemistry and engineering • Advanced molecular biology and informatics • Development of immunological assays • Development of adjuvant technology • Formulation of experimental vaccines using CSL's • proprietary ISCOMATRIX® adjuvant technology Animal models of inflammation and cancer • Experienced Product Development Team CSL has extensive experience in developing large scale plasma protein products and has expertise and facilities to support the production and testing of recombinant proteins, particularly monoclonal antibodies and coagulation factors. The key competencies of the Product Development group are: Cell line development • Manufacture and supply of protein-based products • for clinical trials and commercialisation Dedicated Clinical Development Team CSL has a dedicated and experienced Clinical Research Department that can conduct studies in all phases of clincal development. The group manages all aspects of a clincal trial, from study design, study feasibility, protocol preparation, site indentification and management, through to oversight of data management and preparation of an integrated study report. Commercial Capability CSL markets and sells products globally for haemophilia, critical care, immune disorders and vaccines including influenza. It also markets Merck's cervical cancer vaccine, Gardasil®, in Australia and New Zealand. Research Partnerships CSL creates, patents and adds value to intellectual prop- erty, derived from both internal Australian innovation and partnering with the Australian academic and biotechnology communities. It also has strategic alliances with international pharmaceuti- cal and biotechnology companies, encompassing research and development, manufacturing and marketing activities. R&D is a key element of CSL's future growth strategy and partnerships are integral to the current and future pipeline.